GE8820 / GlycoEra - LARVOL DELTA

A study to investigate safety, and pharmacokinetics, of single n(SAD) and multiple (MAD) ascending doses of GE8820 in healthy adults (ANZCTR) - P1 | N=60 | Not yet recruiting | Sponsor: GlycoEra AG

New P1 trial • Immunology

GE8820: A Selective IgG4 Degrader for the Treatment of Primary Membranous Nephropathy (PMN) (KIDNEY WEEK 2026) - "Conclusion Through selective depletion of the IgG4 subclass, GE8820 removed PLA2R autoantibodies from patient sera . GE8820 is being developed for the treatment of autoimmune diseases driven by pathologic IgG4 autoantibodies such as primary membranous nephropathy, muscle specific kinase driven myasthenia gravis and pemphigus vulgaris."

CNS Disorders • Glomerulonephritis • Immunology • Myasthenia Gravis • Pemphigus Vulgaris • Renal Disease • MUC4

GE8820: a selective IgG4 degrader for the treatment of pemphigus vulgaris (PV) (ESDR 2026) - No abstract available

Dermatology • Immunology • Pemphigus Vulgaris

GE8820: A selective IgG4 degrader for the treatment of pemphigus vulgaris (PV) (SID 2026) - "These data show that IgG4 autoAbs are key drivers of pathogenicity and support the therapeutic potential of an IgG4 degrader in PV treatment. GE8820 is a novel first-in-class IgG4 selective degrader, with potential non-immunosuppressive and steroid sparing activity due to its selective, rapid and deep IgG4 degradation."

Dermatology • Immunology • Pemphigus Vulgaris • MUC4